In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers

Xenobiotica

Volumn 39, Issue 6, 2009, Pages 444-456

  Swaisland, H C ^a   Oliver, S D ^a   Morris, T ^a   Jones, H K ^a   Bakhtyari, A ^b   MacKey, A ^a   McCormick, A D ^a   Slamon, D ^a   Hargreaves, J A ^a   Millar, A ^a   Taboada, M T ^a  

^a ASTRAZENECA   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Cytochrome P450 (CYP) 3A4; Drug interactions; Itraconazole; Rifampicin; ZD4054; Zibotentan

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; HYDROXYITRACONAZOLE; IBUPROFEN; ITRACONAZOLE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; PARACETAMOL; QUERCETIN; RIFAMPICIN; UNSPECIFIC MONOOXYGENASE; ANTINEOPLASTIC AGENT; CYTOCHROME P450; DIMETHYLANILINE MONOOXYGENASE; DIMETHYLANILINE MONOOXYGENASE (N-OXIDE FORMING); ENDOTHELIN A RECEPTOR; OXYGENASE; PYRROLIDINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SPECIFICITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; RADIOACTIVITY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; AGED; CHEMISTRY; DEMOGRAPHY; DRUG ANTAGONISM; DRUG INTERACTION; DRUG SCREENING; HEALTH; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DEMOGRAPHY; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; FEMALE; HEALTH; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; OXYGENASES; PYRROLIDINES; RECEPTOR, ENDOTHELIN A; RIFAMPIN;

EID: 69249209858     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250902810944     Document Type: Article

References (23)

1. Ahonen J, Olkkola KT, Neuvonen PJ. (1996). Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. Ther Drug Monit 18:124-127 (Pubitemid 26102855)
2. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. (1998). The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54:53-58
3. Bagnato A, Natali PG. (2004). Endothelin receptors as novel targets in tumor therapy. J Translation Med 2:16.
4. Boyd MA, Zhang X, Dorr A, Ruxrungtham K, Kolis S, Nieforth K, Kinchelow T, Buss N, Patel IH. (2003). Lack of enzyme- inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol 43:1382-1391
5. Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ, Andre A, Hosmane BS, Padley RJ. (2002). Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 20:2171-2180
6. Clarkson-Jones J, Kenyon A, Kemp J, Lenz E, Oliver S, Phillips P, Sandall D, Swaisland H. (2007). Metabolism of [14C]-ZD4054 in healthy volunteers. Eur J Cancer Suppl. 5:114.
7. James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA. (2009). Safety and efficacy of the specific endothelin A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo- controlled, randomized, Phase II trial. Eur Urol (In Press) doi:10.1016/j. eururo. 2008.11.002
8. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. (2007). Cancer statistics, 2007. CA: Cancer J Clin 57:43-66.
9. Kantola T, Kivisto KT, Neuvonen PJ. (1998). Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58-65.
10. Kasper S, Cookson MS. (2006). Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin N Am 33:201-10, vii.
11. Kopetz ES, Nelson JB, Carducci MA. (2002). Endothelin-1 as a target for therapeutic intervention in prostate cancer. Investig New Drugs 20:173-182
12. la Porte CJ, Colbers EP, Bertz R, Voncken DS, Wikstrom K, Boeree MJ, Koopmans PP, Hekster YA, Burger DM. (2004). Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agent Chemother 48:1553-1560
13. Liu G, Dreicer R, Hou J, Chen Y, Wilding G. (2005). Tolerability profile of ZD4054 is consistent with the effects of endothelin A receptorspecific antagonism. J Clin Oncol 23 (16S):abst 4628.
14. McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD. (2004). Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Hlth Rep 119:174-186
15. Morris C, Wilson D, Hughes A, Le Maulf F, Brahma S, Fuhr R. (2004). ZD4054: specificity for endothelin A receptor following single dose administration in healthy volunteers. Eur J Cancer Suppl. 2:26.
16. Nelson J, Bagnato A, Battistini B, Nisen P. (2003). The endothelin axis: emerging role in cancer. Nat Rev Cancer 3:110-116
17. Neuvonen PJ, Jalava KM. (1996). Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 60:54-61.
18. Ohnhaus EE, Breckenridge AM, Park BK. (1989). Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol 36:39-46.
19. Okazawa M, Shiraki T, Ninomiya H, Kobayashi S, Masaki T. (1998). Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem 273:12584-12592
20. Peloquin CA, Namdar R, Singleton MD, Nix DE. (1999). Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18. (Pubitemid 29047048)
21. Petrylak D. (2005). Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU Int 96 (Suppl. 2):41-46
22. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
23. Salphati L, Benet LZ. (1998). Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol 55:387-395